galera therapeutics, inc. is a pharmaceuticals company located in 101 lindenwood dr, malvern, pennsylvania, united states.
Company profile
Ticker
GRTX
Exchange
Website
CEO
J. Mel Sorensen
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Galera Labs, LLC • Galera Therapeutics Australia Pty Ltd ...
IRS number
461454898
GRTX stock data
Latest filings (excl ownership)
10-K
2023 FY
Annual report
28 Mar 24
8-K
Galera Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Updates
28 Mar 24
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
27 Mar 24
10-Q
2023 Q3
Quarterly report
14 Nov 23
8-K
Galera Reports Third Quarter 2023 Financial Results and Recent Corporate Updates
14 Nov 23
8-K
Galera Announces Receipt of Type A Meeting Minutes and Strategic Update
31 Oct 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
26 Sep 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
22 Sep 23
10-Q
2023 Q2
Quarterly report
14 Aug 23
8-K
Galera Reports Second Quarter 2023 Financial Results and Recent Corporate Updates
14 Aug 23
Latest ownership filings
SC 13G
ALPHA PHARMA Investments LLC
16 Apr 24
SC 13G/A
Altamont Pharmaceutical Holdings, LLC
3 Apr 24
5
Mark E. Pearson
1 Apr 24
4
Yair Schneid
26 Feb 24
SC 13D/A
Sofinnova Venture Partners IX, L.P.
20 Feb 24
SC 13G/A
SECTORAL ASSET MANAGEMENT INC
14 Feb 24
SC 13G
Schneid Yair
17 Jan 24
3
Yair Schneid
16 Jan 24
SC 13G
GSA CAPITAL PARTNERS LLP
2 Jan 24
SC 13D/A
Blackstone Holdings I/II GP L.L.C.
4 Dec 23
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 24.43 mm | 24.43 mm | 24.43 mm | 24.43 mm | 24.43 mm | 24.43 mm |
Cash burn (monthly) | (no burn) | (no burn) | 4.47 mm | 4.77 mm | 4.17 mm | 4.07 mm |
Cash used (since last report) | n/a | n/a | 30.81 mm | 32.93 mm | 28.80 mm | 28.10 mm |
Cash remaining | n/a | n/a | -6.38 mm | -8.50 mm | -4.37 mm | -3.68 mm |
Runway (months of cash) | n/a | n/a | -1.4 | -1.8 | -1.0 | -0.9 |
Institutional ownership, Q3 2023
35.6% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 43 |
Opened positions | 7 |
Closed positions | 26 |
Increased positions | 7 |
Reduced positions | 11 |
13F shares | Current |
---|---|
Total value | 1.52 bn |
Total shares | 19.35 mm |
Total puts | 10.20 k |
Total calls | 2.50 k |
Total put/call ratio | 4.1 |
Largest owners | Shares | Value |
---|---|---|
Sofinnova Venture Partners IX | 3.08 mm | $5.12 mm |
Sofinnova Investments | 3.08 mm | $539.96 mm |
Flynn James E | 2.92 mm | $5.02 mm |
Blackstone Holdings I/II GP L.L.C. | 1.71 mm | $7.83 mm |
BX Blackstone | 1.68 mm | $293.82 mm |
Rosalind Advisors | 1.54 mm | $3.61 mm |
Vanguard | 1.06 mm | $185.06 mm |
Venrock Healthcare Capital Partners III | 917.86 k | $9.39 mm |
Nan Fung | 613.22 k | $107.38 mm |
Novartis Bioventures | 476.09 k | $2.19 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
28 Mar 24 | Altamont Phamaceutical | Common Stock | Sell | Dispose S | Yes | No | 0.1459 | 693,076 | 101.12 k | 1,080,000 |
27 Mar 24 | Altamont Phamaceutical | Common Stock | Sell | Dispose S | Yes | No | 0.1699 | 306,924 | 52.15 k | 1,773,076 |
26 Mar 24 | Altamont Phamaceutical | Common Stock | Sell | Dispose S | Yes | No | 0.1965 | 2,000,000 | 393.00 k | 2,080,000 |
25 Mar 24 | Altamont Phamaceutical | Common Stock | Sell | Dispose S | Yes | No | 0.2189 | 780,000 | 170.74 k | 4,080,000 |
22 Mar 24 | Altamont Phamaceutical | Common Stock | Sell | Dispose S | Yes | No | 0.23 | 20,000 | 4.60 k | 4,860,000 |
8 Feb 24 | Yair Schneid | Common Stock | Buy | Acquire P | No | No | 0.171 | 150,000 | 25.65 k | 8,043,203 |
7 Feb 24 | Yair Schneid | Common Stock | Buy | Acquire P | No | No | 0.1729 | 150,000 | 25.94 k | 7,893,203 |
7 Feb 24 | Yair Schneid | Common Stock | Buy | Acquire P | No | No | 0.17 | 25,000 | 4.25 k | 7,743,203 |
6 Feb 24 | Yair Schneid | Common Stock | Buy | Acquire P | No | No | 0.201 | 25,000 | 5.03 k | 7,718,203 |
5 Feb 24 | Yair Schneid | Common Stock | Buy | Acquire P | No | No | 0.184 | 97,402 | 17.92 k | 7,693,203 |
News
Galera Therapeutics Received A Notice Of Allowance For Its U.S Patent Application 17/378,852 Titled "Pentaaza Macrocyclic Ring Complexes Possessing Oral Bioavailability (To Reduce Oral Mucositis In Head-And-Neck Cancer Patients From Chemoradiation)"
26 Apr 24
12 Health Care Stocks Moving In Friday's After-Market Session
19 Apr 24
12 Health Care Stocks Moving In Wednesday's Intraday Session
17 Apr 24
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
17 Apr 24
12 Health Care Stocks Moving In Friday's After-Market Session
29 Mar 24